mHSPC
mHSPC
Metastatic hormone-sensitive prostate cancer
The UromigosUromigos Live and Unplugged | November 4, 2022
Daniel George, MD, Duke University School of Medicine, gives us insight on what to expect from the future of mHSPC treatment.
Read More
The UromigosUromigos Live and Unplugged | November 4, 2022
Neeraj Agarwal, MD, Professor of Medicine, gives his outlook on the future of cancer care and treatment for mHSPC in 2027.
The UromigosUromigos Live and Unplugged | November 4, 2022
Michael Morris, MD, of Memorial Sloan Kettering Cancer Center gives his predictions for the future of mHSPC treatment.
Akhil Abraham Saji, MDJournal | October 24, 2022
Abiraterone acetate + prednisolone is compared to enzalutamide + AAP for mHSPC cancer starting androgen-deprivation therapy.
Leah LawrenceProstate Cancer | October 18, 2022
Zoledronic acid did not improve survival outcomes in patients outside of metastatic castration-resistant disease.
Patrick DalyESMO 2022 | September 12, 2022
Late-breaking data from 2 randomized phase 3 trials that followed STAMPEDE protocol were presented at the ESMO Congress 2022.
Cecilia BrownmHSPC | August 9, 2022
The FDA has approved the use of darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer.
GU Oncology Now EditorsmCRPC | June 2, 2022
Researchers evaluate the frequency of germline DDRg mutations in metastatic prostate cancer patients of different ancestries.
The UromigosThe Uromigos | July 1, 2021
Eric Small is quizzed about triplet therapy for first-line metastatic prostate cancer.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | February 22, 2021
Adding enzalutamide to androgen deprivation therapy improved progression-free survival in hormone-sensitive prostate cancer.
Advertisement
Advertisement